Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

We plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.

Trial Details

NCT ID

NCT06817525

Phase

PHASE2

Sponsor

Henan Cancer Hospital

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)
6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)

Locations (sample)

Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

Age: 18-65 years old;
Clinically and pathologically confirmed cT2- cT4d, or cT1c with axillary lymph node metastasis;
Three negative type and invasive breast cancer confirmed by histopathology;
Three negative breast cancer is defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →